CN106413712A - 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 - Google Patents

喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 Download PDF

Info

Publication number
CN106413712A
CN106413712A CN201580026812.6A CN201580026812A CN106413712A CN 106413712 A CN106413712 A CN 106413712A CN 201580026812 A CN201580026812 A CN 201580026812A CN 106413712 A CN106413712 A CN 106413712A
Authority
CN
China
Prior art keywords
milligrams
compound
pharmaceutically acceptable
thyroid
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580026812.6A
Other languages
English (en)
Other versions
CN106413712B (zh
Inventor
张喜全
王训强
湛筱乐
于鼎
田心
杨玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN201910645676.9A priority Critical patent/CN111035640B/zh
Priority to CN201910645272.XA priority patent/CN111012785B/zh
Publication of CN106413712A publication Critical patent/CN106413712A/zh
Application granted granted Critical
Publication of CN106413712B publication Critical patent/CN106413712B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物。具体而言，本发明涉及喹啉衍生物1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201580026812.6A 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 Active CN106413712B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910645676.9A CN111035640B (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途
CN201910645272.XA CN111012785B (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410249544.1A CN105213394B (zh) 2014-06-06 2014-06-06 具有抗肿瘤活性的喹啉衍生物
CN2014102495441 2014-06-06
PCT/CN2015/080859 WO2015185011A1 (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910645676.9A Division CN111035640B (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途
CN201910645272.XA Division CN111012785B (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途

Publications (2)

Publication Number Publication Date
CN106413712A true CN106413712A (zh) 2017-02-15
CN106413712B CN106413712B (zh) 2019-08-16

Family

ID=54766181

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201410249544.1A Active CN105213394B (zh) 2014-06-06 2014-06-06 具有抗肿瘤活性的喹啉衍生物
CN201580026812.6A Active CN106413712B (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物
CN201910645272.XA Active CN111012785B (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途
CN201910645676.9A Active CN111035640B (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410249544.1A Active CN105213394B (zh) 2014-06-06 2014-06-06 具有抗肿瘤活性的喹啉衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910645272.XA Active CN111012785B (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途
CN201910645676.9A Active CN111035640B (zh) 2014-06-06 2015-06-05 喹啉衍生物用于治疗甲状腺癌的方法和用途

Country Status (3)

Country Link
KR (1) KR102490547B1 (zh)
CN (4) CN105213394B (zh)
WO (1) WO2015185011A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112043831A (zh) * 2019-06-05 2020-12-08 正大天晴药业集团股份有限公司 用于联合治疗乳腺癌的喹啉类化合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105213394B (zh) * 2014-06-06 2019-04-09 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物
AU2017205749B2 (en) * 2016-01-08 2021-12-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof
CN107296811B (zh) * 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
EP3682883A4 (en) * 2017-09-15 2021-06-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CHINOLINE DERIVATIVE FOR THE TREATMENT OF NEUROENDOCRINE TUMORS
CN109748904A (zh) * 2019-01-31 2019-05-14 正大天晴药业集团股份有限公司 喹啉衍生物的结晶
CN111714498A (zh) * 2019-03-20 2020-09-29 正大天晴药业集团股份有限公司 用于治疗卵巢癌的喹啉衍生物
AU2020278733A1 (en) * 2019-05-23 2022-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivatives for treatment of head and neck cancer
CN112336726A (zh) * 2019-08-09 2021-02-09 正大天晴药业集团股份有限公司 治疗结直肠癌的联用药物组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063739A1 (en) * 2003-12-23 2005-07-14 Pfizer Inc. Novel quinoline derivatives
WO2008095015A2 (en) * 2007-01-30 2008-08-07 The General Hospital Corporation D/B/A Massachusetts General Hospital Method of treating recurrent tumors
CN101809012A (zh) * 2007-03-14 2010-08-18 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法
CN105213394A (zh) * 2014-06-06 2016-01-06 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063739A1 (en) * 2003-12-23 2005-07-14 Pfizer Inc. Novel quinoline derivatives
WO2008095015A2 (en) * 2007-01-30 2008-08-07 The General Hospital Corporation D/B/A Massachusetts General Hospital Method of treating recurrent tumors
CN101809012A (zh) * 2007-03-14 2010-08-18 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法
CN105213394A (zh) * 2014-06-06 2016-01-06 正大天晴药业集团股份有限公司 具有抗肿瘤活性的喹啉衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
柴红等: "甲状腺髓样癌靶向治疗新进展", 《上海交通大学学报( 医学版)》 *
王中和: "《口腔颌面-头颈肿瘤放射治疗学》", 31 August 2013, 上海世界图书出版社公司 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112043831A (zh) * 2019-06-05 2020-12-08 正大天晴药业集团股份有限公司 用于联合治疗乳腺癌的喹啉类化合物

Also Published As

Publication number Publication date
WO2015185011A1 (zh) 2015-12-10
CN111035640B (zh) 2024-03-19
CN111035640A (zh) 2020-04-21
CN111012785A (zh) 2020-04-17
CN105213394A (zh) 2016-01-06
CN106413712B (zh) 2019-08-16
KR102490547B1 (ko) 2023-01-18
CN111012785B (zh) 2024-01-30
CN105213394B (zh) 2019-04-09
KR20170007789A (ko) 2017-01-20

Similar Documents

Publication Publication Date Title
CN106413712B (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物
US10183017B2 (en) Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
CN105311030B (zh) 用于抗肿瘤的螺取代化合物
CN107001326A (zh) 抗非小细胞肺癌的喹啉衍生物
CN109069500A (zh) 一种用于治疗胃癌的喹啉衍生物
CN114652723A (zh) 治疗非小细胞肺癌的喹啉衍生物
CN108601778A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
WO2020057536A1 (zh) 用于治疗脑肿瘤的喹啉衍生物
CN106999485B (zh) 抗肺鳞癌的喹啉衍生物
CN111110681A (zh) 喹啉衍生物联合卡培他滨在治疗肝癌的用途
WO2020057539A1 (zh) 用于治疗小细胞肺癌的喹啉衍生物
CN102755319A (zh) 一种含有普拉格雷和卡维地洛的药物组合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231735

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant